The Pills Keep Coming, and the Court Just Said So

The Supreme Court decided this month to leave the abortion pill where it is, which is to say everywhere, including your mailbox.

The justices preserved access to mifepristone while a lawsuit over the drug continues. That means women can keep getting it at a pharmacy or by mail, with no in-person visit to a doctor required, at least until the case works its way through the system.

The Court granted emergency requests from the drugmakers, who were appealing a Fifth Circuit ruling that would have forced in-person visits and stopped mail delivery. So the makers won the round, and the pills keep moving.

Two justices saw it differently. Clarence Thomas and Samuel Alito dissented, and Thomas did not soften his language about what these companies are doing.

BREAKING: Supreme Court is allowing high-risk abortion drugs to continue flowing into pro-life states while we litigate at the Fifth Circuit.

Mail-order abortion harms women like our client, Rosalie Markezich, who was coerced to take abortion drugs, which ended her child's life.… pic.twitter.com/EXUBMmaFbi

— Alliance Defending Freedom (@ADFLegal) May 14, 2026

Alliance Defending Freedom, which is litigating the case, called it plainly. They said high-risk abortion drugs will keep flowing into pro-life states while the fight continues, and they pointed to a real woman, not a statistic.

Their client, Rosalie Markezich, says she was coerced into taking abortion drugs that ended her child’s life. That is the human cost ADF keeps putting at the center of this, and it is the part the legal briefs tend to scrub out.

Associated Press via CT Mirror described the basic shape of the order this way:

The court’s order allows women seeking abortions to continue obtaining the drug, mifepristone, at pharmacies or through the mail, without an in-person visit to a doctor. Access is likely to remain uninterrupted at least until into next year as the case plays out, including a potential appeal to the high court.

The justices granted emergency requests from makers of mifepristone, who are appealing a federal appeals court ruling that would require women to see a doctor in person and halt delivery of mifepristone through the mail. The federal Food and Drug Administration, which first approved mifepristone for use in abortion in 2000, stopped requiring in-person visits five years ago.

Justices Clarence Thomas and Samuel Alito dissented, with Thomas writing that the two companies, Danco Laboratories and GenBioPro, are not entitled to the court’s action to spare them “lost profits from their criminal enterprise.”

That last line is the whole ballgame for now. The Fifth Circuit had tried to add guardrails, and the Supreme Court hit pause on those guardrails while the case proceeds.

Associated Press via CT Mirror also explained the lawsuit posture and Justice Alito’s dissenting concern:

The court is dealing with its latest abortion controversy four years after its conservative majority overturned Roe v. Wade and allowed more than a dozen states to effectively ban abortion outright.

The case before the court stems from a lawsuit Louisiana filed to roll back the Food and Drug Administration’s rules on how mifepristone can be prescribed. The state claims that the policy undermines the ban there, and it questions the safety of the drug, which has repeatedly been deemed safe and effective by FDA scientists.

Alito, who wrote the opinion overturning Roe, agreed that the state’s efforts have been thwarted by medical providers and private organizations that mail the pills to women in Louisiana, despite the abortion ban. Danco and GenBioPro “are obviously aware of what is going on yet nevertheless supply the drug and reap profits from its felonious use in Louisiana,” he wrote.

Criminal enterprise. That is a sitting Supreme Court justice describing the business model, and he is not wrong to name the profit motive sitting underneath the medical language.

FDA lays out the regulatory history on its own mifepristone page:

Mifeprex (mifepristone) and its generic, Mifepristone Tablets, 200 mg (collectively mifepristone) are approved, in a regimen with misoprostol, to end an intrauterine pregnancy through ten weeks gestation (70 days or less since the first day of a patient’s last menstrual period). The FDA first approved Mifeprex in 2000 and approved a generic version of Mifeprex, Mifepristone Tablets, 200 mg, in 2019.

Risk Evaluation and Mitigation Strategy (REMS) Information Mifeprex and its generic, Mifepristone Tablets, 200 mg, are available under a single, shared system risk evaluation and mitigation strategy (REMS), known as the Mifepristone REMS Program, which sets forth the requirements that must be followed for prescribing and dispensing mifepristone for medical termination of pregnancy through ten weeks gestation.

Under the Mifepristone REMS Program, mifepristone must be prescribed by certified prescribers and must be dispensed by or under the supervision of a certified prescriber or by a certified pharmacy on a prescription issued by a certified prescriber. Under the Mifepristone REMS Program, mifepristone may be dispensed in person or by mail.

So the in-person requirement was dropped years ago. The Fifth Circuit tried to bring it back, and the high court said not yet.

The phrase that should stick with you is the one buried in the FDA’s own description.

Dispensed by mail.

A drug regimen meant to end a pregnancy now arrives in an envelope, no exam, no face-to-face conversation, no one in the room.

Whatever you think about the legal posture, that is a real change in how this happens. The chemical version of abortion has been quietly redesigned for distance and convenience, and the courts are still arguing about whether anyone gets a look at the woman taking it.

Pro-life advocates have not been thrilled with the pace of the federal review under President Trump. The AP noted that anti-abortion groups are pushing the FDA to move faster on a review they hope will produce real restrictions, including on telehealth prescribing.

That frustration is fair, and it is also a signal that the fight is not over. The Supreme Court ruled on an emergency posture, not the merits, which means the door is still open for the Fifth Circuit and the FDA to act.

ADF is treating it exactly that way. They are not packing up.

This is where the patience part comes in. A pause is not a verdict, and an emergency order is not the last word on whether mail-order abortion pills get to keep operating with this little oversight.

The pro-life movement has spent decades being told the fight was finished. It never was.

The legal machinery moves slowly, the drugmakers have deep pockets and a profit motive Thomas named out loud, and the advocates pushing back keep showing up anyway.

So the pills keep coming by mail for now. And the people who think a coerced woman like Rosalie Markezich deserves more than a package on the porch are still standing at the Fifth Circuit, not going anywhere.

What do you think the FDA should do next, and where do you land on mail-order abortion drugs? Tell us in the comments.